1Cheer SM,Wagstaff AJ.Quetiapine.A review of its use in the management of schizophrenia.CNS Drugs,2004,18(3):173～199.
2Nasrallah HA,Tandon R.Efficacy,safety,and tolerability of quetiapine in patients with schizophrenia.J Clin Psychiatry,2002,63 (Suppl 13):12～20.
3Kasper S,Brecher M,Fitton L,et al.Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia.Int Clin Psychopharmacol,2004,19(5):281～289.
4Srisurapanont M,Maneeton B,Maneeton N.Quetiapine for schizophrenia.Cochrane Database Syst Rev,2004,(2):CD000967.
5Cheer SM,Wagstaff AJ.Quetiapine.A review of its use in the management of schizophrenia.CNS Drugs,2004,18(30:173～199.
6Wetterling T.Bodyweight gain with atypical antipsychotics.A comparative review.Drug Saf,2001,24(1):59～73.
7Sussman N.The implications of weight changes with antipsychotic treatment.J Clin Psychopharmacol,2003,23(Suppl 1):S21～26.
8Buckley PF,Goldstein JM,Emsley RA.Efficacy and tolerability of quetiapine in poorly responsive,chronic schizophrenia.Schizophr Res,2004,66(2～3):143～150.
9Stahl SM.Dopamine system stabolizens,aripiprazole,and the next generation If antipsychotics.Pary 2 Clin psychiatry,2001,12:923～4
10Altar CA,Kikuchi T,Hiroset,Tottori K.The antipsychotic aripiprazole:a presynaptic D2 autoreceptor agonist that blocks postsynaptic agonist actions (poster).Presented at:The 37^th annual meeting of the American College of neuropsychopharmacology.San Juan,Puerto rico.December14～18,1998
